Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated
“Now that the clinical protocol for our final marketing Registration Study has been submitted, we are proceeding to sign up investigators and open clinical sites. We are receiving a very positive response and high levels of interest from head and neck cancer physicians who see the abundance of data on Multikine and want to deliver this option to their patients,” stated CEL-SCI CEO Geert Kersten. “We believe that this small 212-patient trial will enroll relatively quickly precisely because Multikine has proven what it can do in terms of safety and efficacy in this specific target patient population which has not had a new option for treatment in decades.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data